Sullivan
Microsoft has discontinued support for Internet Explorer. To access the Sullivan website, please install a modern browser like Microsoft Edge or Google Chrome.

Biography

Viewpoints

Viewpoints

Biotech Focused On Developing Non-Opioid Therapeutics to Alleviate Pain Announced IPO

Sullivan was issuer's counsel for Chromocell Therapeutics Corporation, a clinical-stage biotech company focused on developing and commercializing new, non-opioid therapeutics to alleviate pain, in their $6.6 million initial public offering of common stock.

The Sullivan team was led by David Danovitch, director of the firm’s Corporate Department, with partners Charles E. Chambers Jr., Aaron Schleicher and associate Brian Hurley. Sullivan has developed a strength in working with entrepreneurial biotech and tech companies in the U.S. and in Israel.

David E. Danovitch, Charles E. Chambers Jr. and Brian P. Hurley

Past Events

SEC Establishes Retail Fraud Working Group to Combat Fraud Targeting Everyday Investors
When: July 9, 2026
People: David E. Danovitch, Michael T. Dyson and Erika J. Dennery
Sullivan & Worcester Submits Rebuttal Comment Letter to SEC on Nasdaq’s Proposed Market Value Listing Requirement
When: June 5, 2026
People: David E. Danovitch, Angela Gomes, Brendan O'Brien and Phillip Carnevale
Sullivan & Worcester Submits Supplemental Comment Letter to SEC on Nasdaq’s Proposed Market Value Listing Requirement
When: May 28, 2026
People: David E. Danovitch, Angela Gomes, Brendan O'Brien and Phillip Carnevale
Nasdaq Considers a New $5 Million Market Value Threshold for Continued Listing: What Issuers Need to Know
When: February 19, 2026
People: David E. Danovitch, Joseph E. Segilia, Angela Gomes, Brendan O'Brien and Phillip Carnevale
Sullivan & Worcester Submits Comment Letter to SEC on Nasdaq’s Proposed Market Value Listing Requirement
When: February 17, 2026
People: David E. Danovitch, Angela Gomes and Brendan O'Brien
SGX-Nasdaq Dual Listing Framework - Opening New Doors for East Asian Companies
When: December 15, 2025
People: David E. Danovitch, Tehila Levi Lati and Eric Victorson
FINRA’s Small-Cap Sweep: Strategic Steps for Broker-Dealers
When: December 2, 2025
People: David E. Danovitch, Michael T. Dyson, Meghan Rohan, Christopher K. Shields and Erika J. Dennery
FINRA Launches Targeted Review of Small-Cap Foreign Offerings
When: October 24, 2025
People: David E. Danovitch, Michael T. Dyson, Meghan Rohan and Erika J. Dennery
SEC and CFTC Continue Their Lucrative Pursuits of Penalizing Unapproved Communication Methods
When: August 27, 2024
People: David E. Danovitch, Michael T. Dyson, John Hunt and Erika J. Dennery
SEC’s Proposed Changes to Regulation S-P Would Overhaul Records and Information Requirements of Covered Institutions
When: March 20, 2023
People: Michael T. Dyson, Meghan Rohan and David E. Danovitch